interleukin-17 family

Overview

The interleukin-17 family comprises six structurally related cytokines, IL-17A through IL-17F, that act at epithelial and mucosal surfaces to recruit neutrophils, induce antimicrobial peptides and amplify local inflammation. IL-17A and IL-17F are the central members, secreted as homodimers or as an IL-17A/F heterodimer, and signal through a receptor complex of IL-17RA with IL-17RC. That receptor is unlike most cytokine receptors: it uses neither JAK/STAT nor a kinase of its own, but recruits the adaptor Act1, which engages TRAF6 to activate NF-κB and MAPK pathways — which is why IL-17-driven disease does not respond to JAK inhibitors and why it needs its own class of drugs. The family is functionally heterogeneous, IL-17E (IL-25) driving type 2 rather than neutrophilic responses.

IL-17 is the effector arm of the Th17 program, and its production is induced and sustained upstream by interleukin-23, which is a driver of the response rather than a product of it. Downstream, IL-17 acts largely by amplification: it induces NF-κB-dependent expression of TNF-α, interleukin-6, IL-1β, chemokines and growth factors, and synergizes with TNF-α so that the two together do far more than either alone. Its physiological role is defense against extracellular bacteria and fungi at barrier surfaces, which is why patients with genetic defects in IL-17 signaling — and, more mildly, those given IL-17 blockers — develop chronic mucocutaneous candidiasis.

Blocking the axis is highly effective in plaque psoriasis and psoriatic arthritis, where secukinumab and ixekizumab neutralize IL-17A, brodalumab blocks the receptor, and bimekizumab neutralizes both IL-17A and IL-17F. The same blockade fails in Crohn's disease and can worsen it, consistent with IL-17's role in maintaining intestinal barrier integrity — a clear demonstration that a cytokine's contribution is tissue-specific rather than uniformly pathogenic. Research continues into IL-17 signaling in osteoarthritis, periodontitis, experimental autoimmune encephalomyelitis, neuroinflammation and antiviral responses.

Recent Publications Summary

Recent studies have continued to position interleukin-17 as a relevant target in inflammatory disease modeling and drug discovery. In antiviral research, a screen for anti-RSV compounds identified lapatinib as inhibiting RSV infection through downregulation of interleukin-17, suggesting that suppression of the IL-17 pathway contributed to its antiviral effect 42376990Jun. In a related inflammatory tissue context, a bioinspired hydrogel microsphere system for osteoarthritis was reported to converge on shared anti-inflammatory pathways including TNF-α, NF-κB, and IL-17, promoting macrophage M2 polarization and supporting an anti-inflammatory microenvironment 42319075Jun.

Drug discovery efforts specifically directed at IL-17 inhibition also remained active. A “MicroCycle” workflow was used to prioritize a novel thiazole-based series targeting interleukin-17, with the stated goal of rapidly identifying promising central cores and capping groups to guide optimization 42157731May. In another materials-based therapeutic study, deep-penetrating transdermal lipopeptide liposomes were developed for sustained IL-17 inhibition and prevention of psoriatic recurrence, highlighting ongoing interest in durable pathway blockade for psoriasis management 42325141Jun.

The IL-17 axis was also examined in neuroimmune and autoimmune settings. A study testing chrysin in mice exposed to combined Interleukin-17A and amyloid beta1-42 reported that IL-17 cytokine signaling and its downstream pathways have been implicated in preclinical and clinical models of Alzheimer disease, and the work assessed whether chrysin could ameliorate associated neurochemical and behavioral changes 42149389May. In experimental autoimmune encephalomyelitis, investigators reported that an adaptive cellular source of IL-17A and IL-17F was critical for induction of disease, even as prior studies had suggested IL-17 might be dispensable for EAE induction 42030372Apr.

Human inflammatory disease association studies also reinforced the relevance of IL-17 biology. A systematic review and meta-analysis of periodontitis found significantly higher levels of IL-17, IL-17A, and multiple other inflammatory mediators, including CCL2, IL-1β, IL-6, IL-18, RANKL, and TNF-α, in affected subjects independent of comorbidities 41910651Mar. In intestinal and systemic inflammation research, ALY688 was reported to strengthen intestinal barrier integrity through activation of the RORγt/IL-17 pathway, increasing tight junction proteins such as Claudin-1 and ZO-1 and mucins including MUC19 and MUC22, thereby limiting systemic spillover of bacterial endotoxin and microbial metabolites 42521105Jul.

What Changes, What Holds

1. IL-17 remains a relevant anti-inflammatory and antiviral target, but the new findings only extend known use-cases
REINFORCES Linking RSV inhibition to downregulation of interleukin-17 fits the established view of IL-17 as part of inflammatory amplification, not a new biological role 42376990Jun. The osteoarthritis hydrogel result likewise supports the existing account that IL-17 sits within broader anti-inflammatory network effects and tissue inflammation control 42319075Jun. These are application-specific refinements, not a change in how the axis is understood.

2. New delivery and hit-finding strategies are improving how IL-17 inhibition is pursued, not redefining the target
METHOD The MicroCycle prioritization workflow and the transdermal liposome platform change the drug-discovery and formulation approach around IL-17 blockade, rather than the biology of IL-17 itself 42157731May42325141Jun. Both studies reinforce ongoing therapeutic interest in durable pathway suppression for psoriasis, but they do not establish a new role or overturn any part of the Overview.

3. IL-17 is being pulled into Alzheimer and EAE models in ways that complicate, but do not overturn, the baseline immune story
NEW DIRECTION The Alzheimer-focused work extends IL-17 into neuroimmune pathology, a role the Overview does not specifically cover, while the EAE study argues that adaptive IL-17A/IL-17F sources are important for disease induction, which adds nuance to prior uncertainty about dispensability 42149389May42030372Apr. That tension needs replication and mechanistic clarification, but the established inflammatory and autoimmune framing still stands.

4. Human association data continue to support IL-17 as a marker and mediator of inflammatory disease, while barrier-focused work suggests a protective use of the pathway
REINFORCES Higher IL-17-family signals in periodontitis strengthen the existing link between IL-17 biology and tissue inflammation, leukocyte recruitment, and downstream cytokine networks 41910651Mar. ALY688’s barrier-protective effect through RORγt/IL-17 adds a complementary therapeutic angle, showing that pathway engagement can support mucosal integrity rather than only drive damage 42521105Jul.

Overview update candidates: periodontitis association data; barrier-protective RORγt/IL-17 engagement in intestinal inflammation.